NRI Nuvo Reserch Q1 2012 Result

Yet this company had dreamed all the elements before it in order to advance its growth. However with the disappointing result of anonce and with a product that has been Temporarily rejected by the FDA, I believe that shareholders have been had by management. society increased revenues from 3.8 to 6.2 million. That it will be expected as sales of Pensaid increased. The problem with that is operating expenses. $ 2 million for expenses of sales for a company with a turnover of about 15 million per year -20,000,000. Without counting the bonuses and high salaries of dirigeants.I think this company is a joke for shareholders.